IQVIA Holdings Inc.

IQVIA's R&D Solutions contracted backlog reached $32.1 billion in mid-2025 (5.1% year-over-year growth), with $8.1 billion expected to convert over the next twelve months and a trailing book-to-bill of 1.19x. The TAS segment adds a recurring data subscription layer, and total revenue has grown every fiscal year since 2020.

R&D Solutions represented 54.5% of FY2025 revenue ($8.9 billion) and Technology & Analytics Solutions represented 40.6% ($6.6 billion), with both segments primarily serving pharmaceutical and biotech clients. The correlated end markets mean a sustained pharma R&D funding cycle downturn would affect both revenue streams simultaneously.

IQVIA generates revenue split across Americas (approximately 45%), Europe and Africa (approximately 35%), and Asia-Pacific (approximately 20%) based on FY2024 geographic disclosures, with genuine global trial and data operations across more than 100 countries. No single region dominates, though the Americas weighting means US policy changes carry outsized impact.

The TAS segment benefits from asset-light data distribution economics, but R&D Solutions (54.5% of FY2025 revenue) is heavily people-intensive, requiring proportional headcount growth with each clinical trial engagement. Adjusted EBITDA margin has held in the 23-24% range across FY2023-FY2025, reflecting average scale economics for a mixed services-and-data business with no meaningful incremental operating leverage at the consolidated level.

TAS data subscriptions and R&DS multi-year clinical contracts collectively represent the vast majority of IQVIA's revenue, both tied to regulatory-mandated pharmaceutical development workflows that are mission-critical for drug approval and commercial launch. Contract Sales & Medical Solutions, the only transactional segment, accounts for less than 5% of FY2025 revenue.